IMPACT OF KP.2 BNT162B2 COVID-19 VACCINE ON HEALTH-RELATED QUALITY OF LIFE AMONG SYMPTOMATIC U.S. ADULTS WITH SARS-COV-2 DURING THE 2024-2025 RESPIRATORY SEASON
Author(s)
Alon Yehoshua, PharmD1, Rachel Brathwaite, PhD2, Joseph C. Cappelleri, MPH, MS, PhD1, Tianyan Hu, PhD1, Manuela Di Fusco, PhD1, Meghan Gavaghan, MPH1, Xiaowu Sun, PhD3;
1Pfizer, New York, NY, USA, 2CVS Health, Wellesley, MA, USA, 3CVS Health, Woonsocket, RI, USA
1Pfizer, New York, NY, USA, 2CVS Health, Wellesley, MA, USA, 3CVS Health, Woonsocket, RI, USA
OBJECTIVES: This research evaluated the effect of the Pfizer-BioNTech BNT162b2 KP.2 COVID-19 vaccine on health-related quality of life (HRQoL) during the first week of infection among test-confirmed symptomatic adults in the 2024-2025 respiratory season.
METHODS: Adults testing positive for SARS-CoV-2 at a national pharmacy chain between October 24, 2024, and April 15, 2025, were enrolled (CT.gov: NCT05160636). Participants provided consent within 5 days of testing and completed a self-reported online survey capturing demographics, clinical history, and vaccination status. HRQoL was measured using EuroQol 5-Dimension 5-Level (EQ-5D-5L) utility index (UI UI; range -0.573 to 1, higher scores indicate better health), collected daily post-enrollment and retrospectively recalled for the pre-infection period. Regression-based least-squares mean estimates for changes from pre-infection UI were calculated and compared between KP.2 vaccinated patients and unvaccinated patients. A running average of means was computed for each survey time point to estimate the average daily UI from symptom onset through a median of 7 days post-infection.
RESULTS: Among 608 participants, 106 (17.4%) received the 2024-2025 KP.2 vaccine, and 502 (82.4%) were unvaccinated. The mean age was 45.8 years; 76.5% were female; 53.6% used antiviral treatment; and 57.7% had ≥1 comorbidity. Among vaccinated participants, the mean (SD) time since vaccination was 167.2 (87.6) days. The median time from symptom onset to enrollment was 4 days. At the third survey (median of 7 days from symptom onset), the running average change in UI from pre-infection for the vaccinated group was 0.026 (SE: 0.012, P=0.029) lower than the unvaccinated group, indicating less HRQoL loss among vaccinated individuals.
CONCLUSIONS: BNT162b2 KP.2 vaccine was associated with improved HRQoL in the first week of COVID-19 infection during the 2024-2025 respiratory season. These results reinforce the benefits of COVID-19 vaccination and underscore the importance of remaining up to date with vaccine recommendations.
METHODS: Adults testing positive for SARS-CoV-2 at a national pharmacy chain between October 24, 2024, and April 15, 2025, were enrolled (CT.gov: NCT05160636). Participants provided consent within 5 days of testing and completed a self-reported online survey capturing demographics, clinical history, and vaccination status. HRQoL was measured using EuroQol 5-Dimension 5-Level (EQ-5D-5L) utility index (UI UI; range -0.573 to 1, higher scores indicate better health), collected daily post-enrollment and retrospectively recalled for the pre-infection period. Regression-based least-squares mean estimates for changes from pre-infection UI were calculated and compared between KP.2 vaccinated patients and unvaccinated patients. A running average of means was computed for each survey time point to estimate the average daily UI from symptom onset through a median of 7 days post-infection.
RESULTS: Among 608 participants, 106 (17.4%) received the 2024-2025 KP.2 vaccine, and 502 (82.4%) were unvaccinated. The mean age was 45.8 years; 76.5% were female; 53.6% used antiviral treatment; and 57.7% had ≥1 comorbidity. Among vaccinated participants, the mean (SD) time since vaccination was 167.2 (87.6) days. The median time from symptom onset to enrollment was 4 days. At the third survey (median of 7 days from symptom onset), the running average change in UI from pre-infection for the vaccinated group was 0.026 (SE: 0.012, P=0.029) lower than the unvaccinated group, indicating less HRQoL loss among vaccinated individuals.
CONCLUSIONS: BNT162b2 KP.2 vaccine was associated with improved HRQoL in the first week of COVID-19 infection during the 2024-2025 respiratory season. These results reinforce the benefits of COVID-19 vaccination and underscore the importance of remaining up to date with vaccine recommendations.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
PCR154
Topic
Patient-Centered Research
Topic Subcategory
Patient-reported Outcomes & Quality of Life Outcomes
Disease
SDC: Infectious Disease (non-vaccine), STA: Vaccines